Nu Skin Enterprises (NUS) Q3 2026 earnings summary

Executive summary

• Q3 revenue fell 14.6% YoY to $311.0M; adjusted EPS was $0.10 and GAAP diluted EPS was -$0.02.

• Core business and sales-force metrics remained under pressure, while Rhyz revenue grew 13.2%; priorities include channel engagement, anti-aging offerings, India’s H1 2027 launch and operating efficiency.

Financial highlights

• Q3 revenue declined 14.6% reported and 14.3% in constant currency; FX reduced revenue by $3.9M, or 1.1%.

• Q3 net loss was $0.7M versus net income of $17.1M YoY; adjusted net income was $4.7M.

• Q3 operating income was $5.1M versus $21.6M YoY; gross profit was $202.2M.

• Nine-month revenue was $951.7M, down 14.6% YoY; net loss was $248.7M versus net income of $145.7M.

Outlook and guidance

• Q4 revenue guidance is $310M–$340M, down 16%–8% YoY, with ~1% FX impact; EPS guidance is $0.05–$0.15 GAAP and $0.11–$0.21 adjusted.

• FY2026 revenue guidance is $1.26B–$1.29B, down 15%–13%, with ~1% negative FX impact; EPS guidance is -$5.08 to -$4.98 GAAP and $0.55–$0.65 adjusted.

• Adjusted Q4 guidance excludes ~$5.0M in expected cash-based transition costs; management anticipates sequential revenue growth in Q4.

• Full India market opening is anticipated in H1 2027; 2026 capital expenditures are estimated at $40M–$60M, mainly for Rhyz plant expansion, technology and facility upgrades.